June 2026 Research Update

Across these studies, congenital hyperinsulinism (CHI) did not look like a single treatment journey. Some children were controlled with diazoxide, some needed added medicine, and some ultimately needed surgery, and the studies showed that the CHI type and the gene involved often matched those differences. [1] [2]

In a group of 33 children, about 61% were reported to do well on diazoxide alone, while others needed diazoxide plus octreotide or needed surgery after not responding to medicines. The study also reported that ABCC8 and KCNJ11 variants were linked with poorer diazoxide response and a higher likelihood of pancreatectomy, while HK1 variants were more often linked with diazoxide responsiveness. [1]

For focal CHI (a form affecting a specific area of the pancreas), a single-center review reported that many infants still had surgery and surgery was curative in most. At the same time, about 30% were in a group that did not need continuous tube feeding before surgery, and 4 of 12 in that group did not undergo surgery and were cured before age 6 years, showing that early improvement can happen for some infants. [2]

Feeding and nutrition support stood out as a major part of life with hyperinsulinism in infancy, especially for CHI. In 96 infants diagnosed under 12 months, all CHI infants needed IV dextrose and/or parenteral nutrition at diagnosis, and by 6 months fewer CHI infants were exclusively orally fed (59%) compared with transient hyperinsulinism (95%). Breastfeeding rates were low in both groups and declined over time. [3]

Longer-term complications were uncommon in the focal CHI series, but exocrine pancreatic insufficiency (trouble digesting food due to reduced pancreatic enzyme output) was reported after surgery involving the head of the pancreas. This adds a specific example of the kind of long-term issue that can follow certain operations, even when blood sugar control is cured. [2]

For families, this month mainly adds clarity about why CHI experiences can differ so much between children, rather than introducing a new proven treatment. The human studies suggest that knowing the CHI subtype (such as focal CHI) and the genetic cause can help explain why one child may do well with diazoxide while another may need combination medicine or surgery, and why feeding support can be prolonged in some infants. What remains uncertain is how well these patterns hold across all centers and all gene types, because the studies were from single centers or relatively small groups. [1] [2] [3]

These results may matter most in planning and expectations over time: some infants, especially with focal CHI, may show early improvement before surgery in selected situations, while many still require surgery that is often curative. The feeding study highlights that nutrition strategies and the transition to full oral feeding can be a long process for CHI, which can help families understand why intensive feeding plans are commonly used early on. [2] [3]

This month adds a practical message: some early-life clues point toward persistent CHI, but none of them work well enough on their own. A two-center comparison found clear differences in birth weight patterns between prolonged neonatal hypoglycemia and persistent CHI, yet many infants in both groups were still in the normal birth weight range. [4]

Infants with persistent CHI had a much higher median birth weight percentile than infants with prolonged neonatal hypoglycemia, and large-for-gestational-age status was more common in persistent CHI. At the same time, nearly half of infants in each group had birth weights considered normal for gestational age, which is why the authors concluded birth weight cannot reliably distinguish these conditions by itself. [4]

For families, this evidence may matter now as background understanding rather than something that changes care. The study supports the idea that being bigger at birth can be a clue for persistent CHI, but it also shows why many babies with CHI will not be identified from birth weight alone. What remains uncertain is what combination of signs and tests can best separate prolonged neonatal hypoglycemia from persistent CHI early, since this study points to a need for broader algorithms but did not test one. [4]

This month included two single-patient reports that widen the picture of how CHI can present and how it may unfold over time, plus one lab study focused on insulin receptor blockers. The case reports underline that CHI can be missed when symptoms are nonspecific, and that genetic causes can come with longer-term developmental or seizure concerns that show up later. The lab study explains how certain research compounds block insulin signaling, but it does not show patient outcomes. [5] [6] [7]

One infant had repeated BRUE-like episodes (brief events that can look alarming) that led to CHI being discovered only after checking blood sugar during an episode. The report described low ketones and a strong glucose rise after glucagon, and the infant improved with diazoxide plus hydrochlorothiazide and was able to transition from IV glucose to full feeds. [5]

A separate newborn case described hyperinsulinism-hyperammonemia (HI/HA) due to a new GLUD1 variant found by genetic testing. The infant responded to diazoxide (with hydrochlorothiazide), later had stable glucose off diazoxide, and the report noted later neurodevelopmental issues and seizure-like events around age 3 years, with MRI suggesting delayed myelination. [6]

In laboratory research, a structural study mapped how two insulin receptor antagonists, S961 and Ins-AC-S2, attach to the insulin receptor and stabilize it in an inactive shape. The work also showed that a particular contact site (called site 1-lambda in the paper) helped Ins-AC-S2 block signaling more strongly in cell tests, and weakening that contact reduced its blocking effect. This is early research that helps explain drug design rather than describing CHI treatment in people. [7]

For patients and caregivers, the two case reports mainly add recognition and context: CHI may present as scary brief events or seizures, and identifying hypoglycemia during symptoms can be the turning point in finding the cause. Because these are single cases, they cannot predict what will happen for another child, but they show realistic examples of diazoxide-responsive courses and the role genetic testing can play in explaining a specific form like HI/HA. [5] [6]

The insulin receptor lab study is not directly about CHI diagnosis or treatment in families today. Its value is mainly future-facing: it clarifies how insulin-blocking molecules can keep the receptor switched off, which could matter if such approaches are developed further. What remains unknown from this work is whether these findings translate into safe and effective options in people. [7]